Pulmonx Corporation (4NI)
XDUS 
Summary
4NI Chart
Pulmonx Corporation (LUNG) Q3 2025 Earnings Call Transcript
Pulmonx Corporation ( LUNG ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Glendon French - CEO, President & Director Derrick Sung - CFO & COO Conference Call Participants Dorothy Morgan - Gilmartin Group LLC Nathan Treybeck - Wells Fargo Securities, LLC, Research Division John Young - Canaccord Genuity Corp., Research Division Jason Bednar - Piper Sandler & Co., Research Division Presentation Dorothy Morgan Gilmartin Group LLC Good afternoon, and thank you for participating in today's call. Joining me from Pulmonx are Glen French, President and Chief Executive Officer; and Derrick Sung, Chief Operating Officer and Chief Financial Officer.
Pulmonx Corporation (LUNG) Reports Q3 Loss, Beats Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.36 per share a year ago.
After Plunging 37.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pulmonx (LUNG)
Pulmonx (LUNG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Pulmonx Corporation (4NI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Pulmonx Corporation ever had a stock split?
Pulmonx Corporation Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Glendon E. French CEO | XDUS Exchange | US7458481014 ISIN |
| US Country | 291 Employees | - Last Dividend | - Last Split | 1 Oct 2020 IPO Date |
Overview
Pulmonx Corporation, initially known as Pulmonx, is a commercial-stage medical technology company that specializes in creating minimally invasive devices aimed at treating chronic obstructive pulmonary diseases (COPD). Since its incorporation in 1995 and subsequent name change in December 2013, Pulmonx has been at the forefront of offering innovative solutions for emphysema patients across various regions including the United States, Europe, the Middle East, Africa, the Asia-Pacific, and other international territories. The company's mission is to improve the quality of life for people suffering from severe respiratory conditions through their state-of-the-art medical devices. Headquartered in Redwood City, California, Pulmonx stands as a pivotal player in the respiratory care domain, continuously pushing the boundaries of medical technology for the betterment of patient outcomes.
Products and Services
- Zephyr Endobronchial Valve
A cornerstone of Pulmonx's product lineup, the Zephyr Endobronchial Valve offers an advanced solution for patients grappling with hyperinflation due to severe emphysema. This device is designed to alleviate the breathing difficulties associated with emphysema by controlling air flow and reducing lung volume, thereby enhancing respiratory efficiency and overall patient comfort.
- Chartis Pulmonary Assessment System
The Chartis System comprises a sophisticated balloon catheter and console equipped with state-of-the-art flow and pressure sensors. Its primary function is to conduct a precise assessment of the presence of collateral ventilation in the lung. This critical evaluation helps determine the suitability of patients for the Zephyr valve treatment, ensuring that only those who stand to benefit the most are selected for the procedure.
- StratX Lung Analysis Platform
An innovative cloud-based service, the StratX Platform revolutionizes the treatment planning process for emphysema by utilizing quantitative computed tomography analysis. The platform provides in-depth insights into emphysema destruction levels, fissure completeness, and lobar volume, which are integral in identifying the most appropriate target lobes for Zephyr Valve treatment. Through this personalized approach, healthcare providers can achieve a higher level of precision and effectiveness in managing emphysema, leading to better outcomes for patients.
Contact Information
